Legal Proceedings
−Removed: We are not a party to any material legal proceedings at this time.
−Removed: From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities.
−Removed: Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business.
−Removed: Regardless of the outcome, litigation can have an adverse effect on us because of defense and settlement costs, diversion of management resources and other factors.
+Added: We are currently pursuing claims in two lawsuits that we filed in 2022 against Shoreline Biosciences, Inc.
+Added: (Shoreline) and certain of its founders and officers (collectively referred to as the Shoreline litigations).
+Added: The first suit is pending in San Diego Superior Court against Shoreline and three of its founders, Drs.
+Added: Kaufman (Kaufman), Kleanthis G.
+Added: Xanthopoulos, and Steven Holtzman.
+Added: Our claims stem from Kaufman’s founding of and participation in Shoreline’s business, in breach of his exclusivity obligations to us as our scientific advisor pursuant to a Scientific Advisor Agreement between Kaufman and the Company.
+Added: Our claims include actions for breach of contract, breach of implied covenant of good faith and fair dealing, fraud and deceit, tortious interference, restitution and unfair competition.
+Added: We are seeking monetary damages.
+Added: In the second of the Shoreline litigations, we and Whitehead Institute for Biomedical Research (Whitehead) filed a lawsuit in the U.S.
+Added: District Court for the Southern District of California against Shoreline and Kaufman seeking damages for the defendants’
+Added: infringement of U.S.
+Added: 8,071,369, 8,932,856, 8,951,797, 8,940,536, 9,169,490, 10,457,917, and 10,017,744 (the Whitehead Patents).
+Added: The Whitehead Patents, which we exclusively license from Whitehead, relate to key compositions and methods for reprogramming human somatic cells to a pluripotent state in the generation of induced pluripotent stem cells (iPSCs).
+Added: Shoreline and Kaufman have each filed answers to our complaint denying infringement and alleging invalidity of the Whitehead Patents.
+Added: The Shoreline litigations are in the discovery stage and remain pending.
+Added: On January 20, 2023, a purported stockholder of the Company filed a lawsuit against the Company and certain of its officers captioned Hadian v.
+Added: Fate Therapeutics, Inc.
+Added: District Court for the Southern District of California.
+Added: The complaint alleges that the Company violated the federal securities laws by making allegedly false and/or misleading statements and/or omissions in its public disclosures dating back to April 2020 relating to the Company’s collaboration agreement with Janssen Biotech, Inc.
+Added: (the Janssen Agreement), potential future revenue sources for the Company from the Janssen Agreement, and the termination of the Janssen Agreement.
+Added: We believe that there is no merit to this case and we intend to vigorously defend against it.
+Added: From time to time, we may be subject to various other legal proceedings and claims that arise in the ordinary course of our business activities.
Mine Saf ety Disclosures
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.